Literature DB >> 17325285

The 25-foot walk velocity accurately measures real world ambulation in Friedreich ataxia.

M C Fahey1, L A Corben, V Collins, A J Churchyard, M B Delatycki.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17325285     DOI： 10.1212/01.wnl.0000256037.63832.6f

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  8 in total

1.  Sensitivity of spatiotemporal gait parameters in measuring disease severity in Friedreich ataxia.

Authors:  Sarah C Milne; Darren R Hocking; Nellie Georgiou-Karistianis; Anna Murphy; Martin B Delatycki; Louise A Corben
Journal:  Cerebellum       Date:  2014-12       Impact factor: 3.847

Review 2.  [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].

Authors:  L Husseini; V I Leussink; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

3.  Treatment of walking impairment in multiple sclerosis with dalfampridine.

Authors:  Andrew R Blight
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

Review 4.  Evaluating the progression of Friedreich ataxia and its treatment.

Authors:  Martin B Delatycki
Journal:  J Neurol       Date:  2009-03       Impact factor: 4.849

Review 5.  Pharmacotherapy for Friedreich ataxia.

Authors:  Amy Y Tsou; Lisa S Friedman; Robert B Wilson; David R Lynch
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

6.  A comparison of three measures of upper limb function in Friedreich ataxia.

Authors:  L A Corben; G Tai; C Wilson; V Collins; A J Churchyard; M B Delatycki
Journal:  J Neurol       Date:  2009-10-13       Impact factor: 4.849

7.  Upper Body Physical Rehabilitation for Children with Ataxia through IMU-Based Exergame.

Authors:  Alberto Romano; Martina Favetta; Susanna Summa; Tommaso Schirinzi; Enrico Silvio Bertini; Enrico Castelli; Gessica Vasco; Maurizio Petrarca
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.241

8.  Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.

Authors:  Meheroz H Rabadi; Kimberly Kreymborg; Andrea S Vincent
Journal:  Drugs R D       Date:  2013-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.